Advanced imaging techniques may distinguish which patients’ tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, those for whom treatment with the anti-angiogenic drug cediranib rapidly ‘normalized’ abnormal blood vessels around their tumors and increased blood flow within tumors survived significantly longer than did patients in whom cediranib did not increase blood flow.